Press release
Migraine Drugs Market Size Worth US$ 5.4 Billion by 2028
Migraine Drugs Market Report 2023
Report Highlights
How big is the migraine drugs market?
The global migraine drugs market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2023-2028.
What are migraine drugs?
Migraine drugs, or migraine medications, are pharmaceutical substances specifically designed to alleviate or prevent the symptoms of migraine headaches. Migraines are severe and often debilitating headaches characterized by intense pulsating pain, sensitivity to light and sound, and sometimes accompanied by nausea or vomiting. They are categorized into acute treatment drugs and preventive treatment drugs. Acute treatment drugs are taken during a migraine attack to relieve pain and associated symptoms with ibuprofen or prescription medications such as triptans that work by contracting blood vessels in the brain and minimizing inflammation. Additionally, preventive treatment drugs are taken regularly to minimize the severity and frequency of migraine attacks, including beta-blockers, anticonvulsants, or certain antidepressants. They also help stabilize blood vessels and neurotransmitters, ultimately preventing the onset of migraines.
Request for a sample copy of this report: https://www.imarcgroup.com/migraine-drugs-market/requestsample
What are the growth prospects and trends in the migraine drugs industry?
The migraine drugs market is primarily driven by the rising incidences of migraine among individuals. In addition, migraine is a common neurological disorder affecting millions of individuals, contributing to the rising demand for migraine drugs. Moreover, several technological advancements in the treatment and development of migraine-specific drugs target the underlying causes of migraines, providing effective and rapid relief to patients, thus representing another major growth-inducing factor. Besides this, the rising healthcare expenditure, particularly in developed countries, allows patients access to migraine treatments and helps them prioritize their health and well-being, thus accelerating the sales demand. Along with this, the integration of technology in healthcare and the development of mobile apps, wearable devices, and telemedicine made it easier for patients to manage their condition, thus propelling the demand for complementary drugs. Furthermore, the growing awareness about migraines and their symptoms led to earlier diagnosis and treatment, thus creating a positive market outlook.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Treatment Type:
Abortive Treatment
Preventive Treatment
Breakup by Drug Type:
Triptans
Ergot Alkaloids
NSAIDs
Acetylcholine Inhibitors/ Neurotoxins
Ditans
CGRP mAbs
Others
Breakup by Route of Administration:
Oral
Injectable
Others
Breakup by Distribution Channel:
Hospital-Based Pharmacies
Retail Pharmacies
Others
Breakup by Region:
North America: (United States, Canada)
Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Abbott Laboratories
Allergan Plc (Abbvie Inc.)
Amgen Inc.
AstraZeneca Plc
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
Eisai Co. Ltd.
Eli Lilly and Company
Endo International Plc
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co.
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Limited.
Ask Analyst and Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=2543&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Drugs Market Size Worth US$ 5.4 Billion by 2028 here
News-ID: 3221963 • Views: …
More Releases from IMARC Group
Australia Financial Services Market 2025 | Worth USD 317.7 Billion to 2025-2033
Market Overview
The Australia financial services market size reached USD 201.3 Billion in 2024 and is projected to grow to USD 317.7 Billion by 2033. The market is expected to expand steadily with a compound annual growth rate of 5.2% during the forecast period from 2025 to 2033. Key factors driving this growth include the rising demand for digital banking, regulatory advancements, strong economic performance, increasing fintech investments, and enhanced consumer…
Australia Advanced Carbon Dioxide Sensors Market | Worth USD 103.89 Million 2026 …
Market Overview
The Australia advanced carbon dioxide sensors market size was USD 59.19 Million in 2025 and is expected to grow to USD 103.89 Million by 2034. The market growth is driven by strong government-led emissions reduction policies, enhanced building standards for CO2 monitoring, and the integration of IoT-enabled sensor technologies in smart buildings. These trends are supported by increased focus on indoor air quality and workplace health, fueling innovation in…
Australia Used Car Market Projected to Reach USD 197 Billion by 2033
Market Overview
The Australia used car market was valued at USD 77.2 Billion in 2024 and is projected to reach USD 197 Billion by 2033. The market is experiencing strong growth driven by affordability concerns, rising demand for reliable pre-owned vehicles, and the increasing role of digital platforms that simplify transactions. Economic pressures and the shift toward cost-effective vehicle options are further accelerating expansion, making the used car market a vital…
Australia Electric Truck Market Projected to Reach USD 133.0 Million by 2033
Market Overview
The Australia electric truck market reached USD 17.1 Million in 2024 and is projected to expand to USD 133.0 Million by 2033. With a forecast period spanning 2025 to 2033, the market is growing significantly due to stringent government emissions regulations, rising fuel costs, and advancements in battery and charging infrastructure technologies. Investments in fleet electrification and sustainable transport solutions are further driving market share growth. For further details,…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
